Medtronic Responds To Minneapolis Bridge Collapse, USA

August 8, 2007 – 2:38 am | posted in Aid / Disasters, Blood / Hematology, Public Health

Medtronic (NYSE: MDT) announced that the Medtronic Foundation has pledged 50,000 dollars to the Twin Cities Chapter of the American Red Cross in direct response to a community-wide request for additional resources for the Local Disaster Relief Fund. That fund will be critical to ongoing disaster relief efforts in Medtronic’s hometown community. Medtronic also is encouraging employees to donate blood, and providing them with information on regional blood drives. The Red Cross has indicated that blood donations are badly needed to replenish regular supplies.

About Medtronic

Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. The Medtronic Foundation is committed to helping people live healthy and productive lives. Its grant making is focused in three specific areas: health, education and community.

http://www.medtronic.com

Popularity: 3% [?]

Share This

Also Read

Medtronic Statement Regarding U.S. Supreme Court’s Favorable Decision In Riegel V. Medtronic, Inc.

Synthetic Bone Paste For Orthopedic Procedures Now Available In Europe

Medtronic Announces Agreement With Spinal Neuromonitoring Innovator

Medtronic Announces 2007 “Global Heroes”

Survey Indicates Meniett Therapy Is Preferred Treatment, After Diet Modification, For Management Of Meniere’s Disease

Medtronic Foundation Donates $500,000 To Teach For America

Supreme Court Rules FDA Approval Of Certain Medical Devices Protects Manufacturers From State Lawsuits

Medtronic Trials Confirm Ability Of Interceptor(R) Coronary Filter System And Export(R) Aspiration Catheter To Reduce Major Cardiac Events

Medtronic Wins Medical Design Excellence Awards For Products Related To Activa® Deep Brain Stimulation Therapy And Ear, Nose And Throat Surgery

Alnylam And Medtronic Advance Collaboration On Drug-Device Combinations With RNAi Therapeutics For CNS Diseases